Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.67 |
| ▸ | PGK1 | P00558 | 1/20 | 0.64 |
| ▸ | PGK2 | P07205 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nelarabine SCHEMBL31326718 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL1818971 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL14031852 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL18820 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL13575801 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL2143756 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL18321891 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL13657986 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL20769831 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL29077509 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4541381-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2026-02-04 | — | — | EP | disclosed |
| EP-4545101-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4541380-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4545100-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2025-12-09 | — | — | US | disclosed |
| EP-4541379-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-11-19 | — | — | EP | disclosed |
| EP-4640241-A2 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | Advanced Accelerator Applications S.A. (FR) | 2025-10-29 | — | — | EP | disclosed |
| US-20250295820-A1 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (IT) | 2025-09-25 | — | — | US | disclosed |
| US-12415003-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2025-09-16 | — | — | US | disclosed |
| US-20250270555-A1 | ORGANIC COMPOSITIONS TO TREAT BETA-CATENIN-RELATED DISEASES | ARROWHEAD PHARMACEUTICALS INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-8877801-B2 | Compounds and compositions as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20140235660-A1 | COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651917-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| WO-2013105022-A2 | ORGANIC COMPOSITIONS TO TREAT BETA-CATENIN-RELATED DISEASES | NOVARTIS AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| US-8445440-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080260-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | CYP2C19 4884/4885ADORA2A 4582/4885ADORA3 4723/4885 |
| US-12415003-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | CYP2C19 1172/4885ADORA2A 1371/4885ADORA3 1648/4885 |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | CYP2C19 4884/4885ADORA2A 4653/4885ADORA3 4661/4885 |
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | CYP2C19 1172/4885ADORA2A 1371/4885ADORA3 1648/4885 |
| US-20140235660-A1 | COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | CYP2C19 146/4885ADORA2A 528/4885ADORA3 285/4885 |
| US-20250295820-A1 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | CYP2C19 1172/4885ADORA2A 1371/4885ADORA3 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.